Predict your next investment

Curative company logo
Corporation
HEALTHCARE | Medical Equipment & Supplies
curative.com

See what CB Insights has to offer

Partners & Customers

5

About Curative

Curative is working to build alternate supply sources of many of the major sample collection and extraction kit components that use flocked cotton swabs, and scalable RNA extraction methods that do not rely on the supply-constrained magnetic silica beads. Its test can be self-administered at home with a 24-48 hour turnaround time between testing and results.

Curative Headquarter Location

430 S Cataract Ave

San Dimas, California, 91773,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Curative Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Curative Rank

Research containing Curative

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Curative in 3 CB Insights research briefs, most recently on Apr 9, 2020.

Latest Curative News

FDA grants Curative request to revoke COVID-19 test EUA, company pivots to Abbott kits after false result risk

Jul 16, 2021

Published July 16, 2021 Dive Brief: FDA has revoked the emergency use authorization for Curative's COVID-19 test, at the request of the company, six months after the agency issued an alert about the risk of false results. The EUA was granted  to the Curative test in April 2020, making it one of the first COVID-19 kits cleared for use with saliva samples. However, by January 2021, FDA had concerns about false results potentially linked to sample collection. FDA said in a Thursday update to its safety communication on the test that the revocation, effective July 15, was requested by Curative "because the company is now using different EUA-authorized tests for the testing offered at its laboratories. " Curative is using its labs to process other tests, namely the Abbott Alinity m SARS-CoV-2 Assay and a CLIA-validated test based on the CDC SARS-CoV-2 multiplex assay. Dive Insight: The introduction of the Curative test, which was brought to market in collaboration with KorvaLabs, was hailed as a win in the effort to scale up U.S. diagnostic capacity after a slow start early in the pandemic. Curative designed the test for use with swabs or oral fluid specimens. With swabs in short supply early in the crisis, the saliva option removed one bottleneck to testing. Curative was reportedly processing 150,000 COVID-19 saliva samples a day by January 2021, less than one year after it was founded as a sepsis startup. The company's pivot to COVID-19 helped Los Angeles and other U.S. cities including Seattle scale up their testing capacity. However, the test at the heart of the operation is now off the market. At the request of Curative, FDA revoked the EUA on Thursday. "The test that is the subject of this safety communication is no longer being offered and is no longer authorized for emergency use by the FDA," the agency said in Thursday's announcement. The FDA notice comes one month after Curative disclosed a partnership with Abbott. The agreement positioned Curative to offer the Alinity m SARS-CoV-2 Assay from early July. Curative also secured access to Abbott's Alinity m Resp-4-Plex, equipping it to test for SARS-CoV-2, Flu A, Flu B, and RSV in one kit. In a statement, Curative said it will use the Alinity m SARS-CoV-2 Assay to detect the coronavirus in nasal swabs self-collected at a healthcare location. Curative also used a CLIA-validated test based on the CDC SARS-CoV-2 multiplex assay to test for the virus in upper or lower respiratory specimens. The portfolio of kits equips Curative to test asymptomatic and symptomatic people and run pooled tests. The Abbott deal also positions Curative to test for multiple respiratory pathogens that can manifest in similar symptoms but need treating differently. The feared simultaneous waves of SARS-CoV-2 and influenza never materialized last winter but there are concerns for this season and there is already evidence of rising cases of respiratory syncytial virus. Curative said that it made the decision to discontinue its PCR COVID-19 test and asked the FDA to revoke the EUA "as it is no longer needed" with a suite of new testing offerings for patients at its 15,000 sites in more than 20 states.

Curative Acquisitions

1 Acquisition

Curative acquired 1 company. Their latest acquisition was KorvaLabs on May 19, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/19/2020

Acquired

3

Date

5/19/2020

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

3

Curative Partners & Customers

5 Partners and customers

Curative has 5 strategic partners and customers. Curative recently partnered with Abbott on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/16/2021

Licensor

Abbott

United States

FDA grants Curative request to revoke COVID-19 test EUA, company pivots to Abbott kits after false result risk

The FDA notice comes one month after Curative disclosed a partnership with Abbott .

1

1/5/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/1/2020

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/15/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/20/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/16/2021

1/5/2021

8/1/2020

6/15/2020

3/20/2020

Type

Licensor

Vendor

Client

Partner

Partner

Business Partner

Abbott

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

FDA grants Curative request to revoke COVID-19 test EUA, company pivots to Abbott kits after false result risk

The FDA notice comes one month after Curative disclosed a partnership with Abbott .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Curative Team

8 Team Members

Curative has 8 team members, including current Chief Executive Officer, Jeffrey Bowling.

Name

Work History

Title

Status

Jeffrey Bowling

Chief Executive Officer

Current

Fred Turner

Chief Executive Officer

Current

Tami Ciranna

Prolacta Bioscience, and Arthur Andersen

Chief Financial Officer

Current

Lee Spraggon PhD

Chief Technology Officer

Current

Isaac Turner

Chief Information Officer

Current

Name

Jeffrey Bowling

Fred Turner

Tami Ciranna

Lee Spraggon PhD

Isaac Turner

Work History

Prolacta Bioscience, and Arthur Andersen

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Technology Officer

Chief Information Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.